In 2020 more than 80 million people have glaucoma worldwide and this number is expected to increase according to medicals predictions. Unfortunately, glaucoma has no symptoms in its early stages. Glaucoma can be treated with medical therapy, laser therapy or incisional surgery. The main goal in the treatment of glaucoma is to decrease the level of intraocular pressure (IOP). For almost 20 years only prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists were used for medical therapy. The new class of glaucoma medications is the Rho kinase inhibitors that inhibit the downstream pathway of the Rho family of small G-proteins to increase outflow from the conventional (trabecular) outflow pathway in the eye. Two of these Rho kinase inhibitors, ripasudil and netarsudil, have recently launched in the market and are used in clinical practice in some countries. These drugs act as adjuncts to already established medical therapy for further decreasing IOP in the treatment of glaucoma.
ChemDiv can offer a variety of protein kinase inhibitors. Check out our libraries that according to the latest articles can be used in potential glaucoma treatment:
✔️ https://store.chemdiv.com/catalog/targets/protein_kinases_inhibitors_library/ ✔️ https://https://store.chemdiv.com/catalog/targets/kras_targeted_library/